NOVEN ACQUIRES COMMERCIAL RIGHTS TO MINIVELLE™ (ESTRADIOL TRANSDERMAL SYSTEM) Miami, FL and New York, NY, [December 3], 2012 - Noven Pharmaceuticals, Inc., a wholly- owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has acquired commercial rights to Minivelle™ (estradiol transdermal system) in the U.S. and Canada. Noven acquired the rights from Novogyne Pharmaceuticals, a women's health joint venture between Noven and Novartis Pharmaceuticals Corporation. Financial terms of the transaction were not disclosed. The U.S. Food and Drug Administration approved Minivelle™ for the treatment of moderate to severe vasomotor symptoms due to menopause on October 29, 2012....
↧